BioCentury | Dec 18, 2006
Clinical News

MG98: Development discontinued

...TSX:MYG), Montreal, Quebec MGI Pharma Inc. (MOGN), Bloomington, Minn. Product: MG98 Business: Cancer Molecular target: DNA methyltransferase mRNA...
BioCentury | May 23, 2005
Clinical News

MG98: Phase I data

...TSE:MYG), Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Molecular target: DNA methyltransferase mRNA...
BioCentury | May 23, 2005
Clinical News

MG98: Phase II data

...TSE:MYG), Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Molecular target: DNA methyltransferase mRNA...
BioCentury | Oct 11, 2004
Clinical News

MG98: Phase II start

...at 6 month intervals. MethylGene Inc. (TSE:MYG), Montreal, Quebec Product: MG98 Business: Cancer Molecular target: DNA methyltransferase mRNA...
BioCentury | Oct 6, 2004
Clinical News

MethylGene starts MG98 Phase II

...be complete by the second half of 2007. MG98 is a second-generation antisense compound targeting DNA methyltransferase mRNA...
BioCentury | Nov 24, 2003
Company News

MethylGene other research news

...LSE:VER; VNLS, Cambridge, U.K.). MethylGene Inc. , Montreal, Quebec Product: MG98 second-generation antisense compound targeting DNA methyltransferase mRNA...
BioCentury | Apr 7, 2003
Clinical News

MG98: Phase I

...MOGN), Minneapolis, Minn. Business: Cancer Product: MG98 Molecular target: DNA methyltransferase mRNA Description: Second-generation antisense oligonucleotide targeting DNA methyltransferase mRNA...
BioCentury | Jul 15, 2002
Clinical News

MG98: BBG said MOGN started Phase I studies of continuous 2 week infusions of MG98 in undisclosed number of patients. BBG has European rights to MG98 under a Fe

...Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Therapeutic category: Antisense Target: DNA methyltransferase mRNA...
BioCentury | Jul 15, 2002
Clinical News

MG98: BBG plans to start next quarter a Phase I study of a continuous infusion of MG98 over 2 weeks to treat solid tumors in an undisclosed number of patients.

...Cancer Product: MG98 Therapeutic category: Antisense Description: Second generation antisense oligonucleotide targeting DNA methyltransferase Target: DNA methyltransferase mRNA...
BioCentury | Jul 15, 2002
Clinical News

MG98: Phase II

...Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Therapeutic category: Antisense Target: DNA methyltransferase mRNA...
Items per page:
1 - 10 of 15